CDK12 is often mutated in ovarian and prostate cancer and CDK12 deficiency may thus prove useful as a biomarker of PARP inhibitor response (The Cancer Genome Atlas Research Network 2011; Bajrami et al. 2014; Wu et al. 2018). This evidence concerns the gene PARP1 and prostate cancer.